Roche's Xofluza Reduces Flu Symptoms In Children
Executive Summary
The Swiss group's one-dose drug, seen as a future growth driver, is as effective as its off-patent blockbuster Tamiflu in treating children.
You may also be interested in...
Roche Expects Better Xofluza Sales After New Indication
Flu treatment is newly approved for patients at higher risk of flu complications, and Roche is studying other patient groups that could help expand its potential market.
UK's AMRC Licenses Shionogi Superbug Therapy
As it waits for a US FDA decision on its antibiotic cefiderocol, the Japanese company has handed over the rights to a Pseudomonas aeruginosa therapy that will go into the clinic next year.
Prophylaxis Results Set Stage For Expanded Japan Xofluza Use
Shionogi’s novel single-dose flu drug shows promise in first Phase III results in post-exposure prevention, paving the way for a Japanese filing in this setting and potentially expanding already healthy sales.